Inhibition of the lipid metabolism was achieved using both a molecular approach, i.e., transfection of small interfering RNAs (siRNA) and the FASN inhibitor orlistat, a well known anti-obesity drug [23], which has been shown to display antitumor effects [24] and has been already tested in clinical trials in cancer patients [25]. Here, FASN is linked to cancer.